LIFE

(redirected from Losartan Intervention for Endpoint Reduction in Hypertension)
Category filter:
AcronymDefinition
LIFELifetime Television (cable network channel)
LIFELife and Health Insurance Foundation for Education
LIFELove Is for Everyone (various organizations)
LIFELiving Is for Everyone (various organizations)
LIFELosartan Intervention for Endpoint Reduction in Hypertension (drug trial)
LIFELiteracy Initiative for Empowerment (UNESCO)
LIFELiving in Full Expectation (ministry)
LIFELiving in Faith Everyday
LIFELife is for Everyone (anti-abortion group)
LIFELiving Intentionally for Excellence (life leadership)
LIFELearning in Informal and Formal Environments
LIFELiving in Faith Everywhere (ministry)
LIFELiving in Fear Everyday
LIFELaboratory for International Fuzzy Engineering
LIFELiving Isn't for Ever
LIFELiteracy Is for Everyone
LIFELingnan Institute of Further Education (Hong Kong)
LIFELaser-Induced Fluorescence Emission
LIFELegal Immigration Family Equity Act of 2000
LIFELasallian Institute for the Environment
LIFELeaders in Fitness Education (Australia)
LIFELearning Institute for the Fullness of Life and Empowerment (Philippines)
LIFELiving Implants From Engineering
LIFELaser IRCM (Infrared Countermeasures) Flyout Experiment
LIFELifting Individuals for Eternity
LIFECommunity Financial Instrument for the Environment
LIFELight-Ion Facility Europe
LIFELiving In Fullness Everyday
LIFELaser Infrared Flyout Experiment
LIFELive in Freedom Everyday
LIFELikelihood Function Estimation
LIFELive in Full Effect
LIFELiving in Faithful Evangelism
LIFELeaders in Freshman Engineering (Texas A&M)
LIFELong Island Fiber Exchange Inc.
LIFELong Island Funders Exchange (New York)
LIFELess Intensive Farming and Environment Project
LIFELocal Independent Framing Expert
LIFELawrence Inter-Faith Endeavor (food bank in Lawrence County, Indiana, USA)
LIFELiving Injury Free Everyday
LIFELivingston's Informed Friends of the Environment
LIFELessons Intended for Everyone (R. King & Associates)
LIFELiving in Freedom Everlasting
LIFELearning Immune Functioning Enhancement
LIFELoyalty Integrity Fairness Excellence (Nassau County Police Department's Mission Statement, Long Island, NY, USA)
LIFELaboratory Initiated Fetal Emplacement
LIFELook.Inward.For.Evolution (self-development workshops conceived by Alan Mallinick)
LIFELegacies Involving Future Empowerment
LIFELinear Information Flow Edge-Following (network communication algorithm)
LIFELobby for the Individual Freedom and Equality
LIFELove Is Forever Evolving (blog)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Okin presented a secondary analysis of the earlier landmark LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) trial that's diametrically at odds with the main finding in SPRINT (Systolic Blood Pressure Intervention Trial): Namely, in LIFE (Lancet.
These included the International Nifedipine GITS Study of Intervention as a Goal in Hypertension Treatment (INSIGHT), (23) the Nordic Diltiazem (NORDIL) study, (24) the Australian National Blood Pressure Study 2 (ANBP2), (28) the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial, (26) the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial, (29) and the Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) study.
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial revealed no significant differences in achieved SBP/DBP between losartan and atenolol in patients with essential hypertension and left ventricular hypertrophy (LVH).
In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, and Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial, the "winning" strategy for cardiovascular protection was the one backed by the trial's commercial sponsors and also the one that resulted in significantly lower blood pressure than the comparator, he said.
In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, and Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial, the "winning" strategy for CV protection was the one backed by the trial's commercial sponsors--and also the one that resulted in significantly lower blood pressure than the comparator, he said.
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol.
In the Losartan Intervention for Endpoint Reduction in Hypertension trial, stroke was markedly reduced in ARB-treated patients vs.